Study number | Names of separate domains for attrition bias in the Risk of Bias table |
---|---|
158, 197 | Short-term, long-term |
240 | End-of-intervention, end of follow-up |
250, 459, 533 | Subjective outcome measures, objective outcome measures |
285 | Clinical heart failure, subclinical heart failure (dichotomous and/or continuous), overall survival, tumor response, quality of life, adverse effects, adverse effects other than cardiac damage |
302 | Drop-out rate described and acceptable, participants analyzed in the group to which they were allocated |
312 | Mortality (all cause), hospital readmissions (all cause), hospital readmissions (due to adverse drug events), hospital emergency department contacts (all-cause), hospital emergency department contacts (due to adverse drug events), adverse drug events |
316 | Adverse events: hypothyroidism, development or worsening of Graves’ ophthalmopathy, health-related quality of life, participants in euthyroid state, recurrence of hyperthyroidism, socioeconomic effects |
324 | 12 weeks or less, after 12 weeks |
340 | Primary outcomes, secondary outcomes |
346 | All outcomes: drop-outs, all outcomes: ITT analysis |
394 | Time to resolution of diabetic ketoacidosis, all-cause mortality, hypoglycemic episodes, morbidity, socioeconomic effects |
427 | Drop-outs reported, ITT analysis reported |
499 | Objective outcome (deaths), subjective outcome (quality of life) |
638, 795 | Drop-outs, ITT analysis |
641 | Pain, function |
722 | Short term follow-up (up to 3 months), longer term follow-up |
761 | Consumption outcome, selection outcome |
805 | Hemodynamic data, clinical outcomes |
867 | Survival, tumor response, toxicity, quality of life |
943 | Short-term outcomes, childhood outcomes |
946 | All outcomes, ITT analysis |
949 | Wound healed, wound area, time to healing |
951 | Pain, swelling, function, adverse effects |